Nabriva XENLETA gets European approval for community-acquired pneumonia

The EMA approved Nabriva Therapeutics’ (NASDAQ:NBRV) XENLETA for the treatment of community-acquired pneumonia.

The approval is based on efficacy data from two Phase 3 clinical trials, both of which established XENLETA to be non-inferior to the standard-of-care moxifloxacin in the treatment of community-acquired pneumonia in adults. 

“The marketing authorization of XENLETA provides an important step forward for patients with community-acquired pneumonia, offering the first new antibiotic class approved by the EMA in nearly two decades,” Ted Schroeder, Nabriva’s CEO, said in a statement.

“Along with its short course, monotherapy regimen, and availability of both intravenous and oral formulations, XENLETA offers an important empiric treatment option for adult patients with community-acquired pneumonia, aligned with the core principles of antimicrobial stewardship,” he added.

The FDA approved XENLETA for the treatment of adult patients with community-acquired bacterial pneumonia in August 2019.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.